FDA Grants Orphan Drug Designation to 7MW3711 for SCLC
The United States Food and Drug Administration (FDA) has granted orphan drug designation to the antibody-drug conjugate (ADC) 7MW3711 for the treatment of small cell lung cancer (SCLC), according to an announcement from Mabwell, the drug developer. The novel B7-H3–targeting ADC is composed of an “innovative antibody molecule, novel linker, and novel payload Mtoxin (TOP1i),” according to Mabwell. ...
Advertisement
Advertisement
Advertisement

DocWire Content Partners

Powered by DocWire News

The Latest From GI Oncology Now

The Latest From Heme Today

Expert Interviews

Network Websites